Research for treatments, prevention and a cure
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Prevention and Vulnerable Populations (PVP)

CTNPT 004: Effects of HLA allele frequencies on HIV disease progression

Trial Results

Print Friendly, PDF & Email

Effects of HLA allele frequencies on HIV disease progression and viral load among newly diagnosed HIV infected individuals in Manitoba


When HIV is acquired it infects the immune cells and causes a decline in a specific type of immune cell called CD4+ T-cells. Variation in the human leucocyte antigen (HLA) gene can influence the rate of CD4 decline. These genes are responsible for cellular molecules that help the immune system distinguish between the body’s own proteins and invading viruses.

The effect of the variations in this gene have been studied in both Caucasian and African patients however very little attention has been paid to those of Aboriginal descent. This population is over-represented among those living with HIV in Canada, particularly in the prairie provinces (Saskatchewan and Manitoba). This study investigated the association between HLA variations and CD4 decline in Manitoba 

Study Population

Two-hundred and ninety-four HIV positive participants were recruited and analyzed for their variation in HLA. Fifty-six recruited participants had the B35 variation of HLA, the B51 variation was present in 58 participants, and 10 individuals had both. One-hundred and eighty other participants were included as a control group (neither B35 nor B51).

Study Design

The study measured the CD4 count at the beginning of the study, the rate of CD4 decline, HIV viral load, and opportunistic infections, among other things. The number of participants whose CD4 cell count fell below 200 cells/mL and/or had opportunistic infections was compared between the groups.


Both HLA B51 and HLA B35 were found to be associated with a progression to AIDS, reaching a CD4 T-cell count of <200 cells/mL, and/or opportunistic infections. The study also found that the HLA B35 was more prevalent in this population than in other groups of people. 


This study identified three major findings: (1) supported the association between the B35 variation and increased disease progression, (2) the B35 variation was found to be overrepresented in the study population, and (3) for the first time the HLA B51 variation was found to be associated with a faster CD4 decline.

Additional Information

Principal Investigators:
Drs. Ken Kasper, Marissa Becker, & Yoav Keynan
University of Manitoba
Ph: 204-787-3633


Keynan Y, Becker M, Rueda Z, Bresler K, Kasper K. Rapid human immunodeficiency virus disease progression is associated with human leukocyte antigen-B homozygocity and human leukocyte antigen-B51 in a cohort from Manitoba, Canada. Infectious Diseases. 2015 Mar;47(7):447–52.

Keynan Y, Rueda ZV, Bresler K, Becker M, Kasper K. HLA B51 is associated with faster AIDS progression among newly diagnosed HIV-infected individuals in Manitoba, Canada. Int J Immunogenet. 2015 Aug;42(5):336–40.

Latest News

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Call for Nominations: Community Advisory Committee (CAC) 2018

| Uncategorized | No Comments

The CIHR Canadian HIV Trials Network (CTN/Network) is an innovative partnership funded by the Canadian Institutes of Health Research to…

Guest Blog: Dr. Nadine Kronfli on HCV treatment in Canadian prisons

| Hepatitis C | No Comments

Persons in custody in Canadian prisons have a 25-fold higher rate of hepatitis C (HCV) infection than the general population….

Guest Blog: CTN Postdoc Dr. Malika Sharma

| Uncategorized | No Comments

CTN Postdoctoral Fellow Dr. Malika Sharma writes about the current state of PrEP in Canada and how CTN 303 looks to change the way these HIV prevention drugs are delivered.

Research for treatments, prevention and a cure